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Abstract
Background:  Introduction:  Raynaud’s  phenomenon  (RP)  is  a  well-deﬁned  clinical  syndrome.  Sys-
temic sclerosis  (SSc)  is  the  most  frequent  associated  disease  to  RP  (96%).  The  aim  of  this  study
was to  assess  the  differences  between  primary  RP  (PRP)  and  secondary  RP  (SRP)  regarding
macrovascular  disease  parameters,  endothelial  dysfunction  and  angiogenesis  biomarkers.
Materials  and  methods:  Flow-mediated  dilatation  (FMD),  endothelin-1  (ET-1),  asymmetric
dimethylarginine  (ADMA)  vascular  endothelial  growth  factor  (VEGF),  endoglin  and  endostatin
were analyzed  in  a  cohort  study  of  32  PRP  patients  and  77  SRP  all  with  SSc.  38  of  the  SRP
SSc-associated  patients  had  severe  digital  ulcer  (DU).
Results:  Patients  with  PRP  had  signiﬁcantly  longer  history  of  RP  compared  to  SRP  SSc-sssociated
patients (p  =  0.028).
FMD  was  signiﬁcantly  lower  in  SRP  patients  10.85  ±  11.0%  (p  <  0.001),  more  evidenced  in
SRP SSc-associated  DU  patients  5.34  ±  7.49  (p  <  0.001).  ET-1  plasma  levels  were  signiﬁcantly
increased  in  both  PRP  7.53  (0.16--11.73)  and  SRP  patients  11.85  (7.42--17.23)  (p  <  0.001).
Signiﬁcant increased  serum  levels  of  ADMA  0.52  (0.45--0.63)  mol/L  (p  <  0.001)  and  endoglin
3.01 (1.46--7.02)  mg/ml  (p  <  0.001)  were  found  in  the  SRP  SSc-associated  group  with  DU.
VEGF was  signiﬁcantly  decreased  in  the  DU  group  245.06  (158.68--347.33)  pg/ml  compared
to PRP  438.50  (269.26-854.00)  pg/ml  and  SRP  naïve--DU  patients  290  (166.71--361.78)  pg/mliﬁcant  differences  were  found  between  groups  regarding  endostatin
Sc-associated  patients  without  DU  no  statistically  signiﬁcant  differ-
ADMA,  VEGF,  plasma  levels  were  observed.patients (p  <  0.001).  No  sign
(p =  0.118).
Comparing  PRP  and  SRP  S
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Conclusion:  Overproduction  of  ET-1  and  VEGF  is  present  in  PRP  patients.  Macrovascular  disease
and an  impaired  response  to  shear  stress  are  more  characteristic  of  SRP  with  a  grater  expression
in patients  with  peripheral  ischemic  lesions.
© 2016  Sociedade  Portuguesa  de  Angiologia  e  Cirurgia  Vascular.  Published  by  Elsevier  Espan˜a,
S.L.U. This  is  an  open  access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.
org/licenses/by-nc-nd/4.0/).
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Vasculopatia  periférica  no  fenómeno  de  Raynaud:  o  papel  dos  biomaracdores
Resumo
Introduc¸âo:  O  Fenômeno  de  Raynaud  (FR)  é  uma  patologia  clínica  comum,  caracterizada  por
episódios recorrentes  de  vasospasmo  das  artérias  digitais  desencadeados  pela  exposic¸ão  ao  frio
ou pelo  stress  emocional.  O  FR  pode  ser  classiﬁcado  como  sendo  primário  (FRP)  idiopático
ou secundário  (FRS)  se  associado  a  outras  patologias  ou  condic¸ões,  a  mais  frequente  a  escle-
rodermia.  O  objectivo  deste  estudo  foi  a  identiﬁcac¸ão  de  diferenc¸as entre  o  FR  primário  e
o secundário  no  que  respeita  a  parâmetros  de  avaliac¸ão  de  doenc¸a  macrovascular,  disfunc¸ão
endotelial  e  angiogenese.
Material  e  métodos: Foram  analisados  parâmetros  clínicos  e  demográﬁcos,  avaliada  a  doenc¸a
macrovascular  com  o  teste  de  Allen  e  a  ﬂuxo  mediada  pelo  dilatac¸ão  (FMD),  doenc¸a  microvas-
cular através  da  videocapilaroscopia  periungueal  (NVC),  foi  feita  a  pesquisa  de  autoanticorpos
e medidos  os  biomarcadores  de  doenc¸a  vascular  de  disfunc¸ão  endotelial  (a  endotelina-1-ET-1  e
dimetilarginina  assimétrica-  ADMA)  e  de  angiogênese  (fator  de  crescimento  endotelial  vascular-
VEGF, endostatina  e  endoglina)  em  todos  os  doentes  e  no  grupo  controle.
Resultados:  Doentes  com  FR  primário  tinham  durac¸ão  de  doenc¸a  superior  aos  FRS  (p  =  0.028).
O FMD  era  signiﬁcativamente  menor  nos  doentes  com  FRS  10.85  ±  11.0%  (p  <  0.001),  e  nestes
a resposta  era  pior  nos  doentes  com  úlcera  activa  5.34  ±  7.49  (p  <  0.001).  Os  níveis  plasmáti-
cos de  ET-1  estavam  signiﬁcativamente  aumentados  nos  doentes  com  FRP  7.53  (0.16-11.73)
e nos  FRS  11.85  (7.42-17.23)  (p  <  0.001).  No  grupo  com  úlcera  activa  veriﬁcou-se  níveis  séri-
cos aumentados  de  ADMA  0.52  (0.45-0.63)  umol/L  (p  <  0.001)  e  de  endoglina  3.01  (1.46-7.02)
mg/ml (p  <  0.001).  Pelo  contrário  este  grupo  apresentava  valores  inferiores  de  VEGF  245.06
(158.68-347.33)  pg/ml  comparado  aos  FRP  (269.26-854.00)  pg/m  e  aos  FRS  sem  úlcera  290
(166.71-361.78)  pg/ml  (p  <  0.001).  No  que  respeita  ao  biomarcador  angiostático  endostatina
não identiﬁcamos  diferenc¸as  entre  grupos  (p  =  0.118).
Os doentes  com  FRP  e  os  SRPN  sem  lesão  vascular  periférica  não  apresentavam  diferenc¸as
signiﬁcativas  nos  biomacadores  estudados.
Conclusão:  Os  doentes  com  FRP  tem  níveis  elevados  de  ET-1  e  VEGF.  A  doenc¸a  macrovascular
com uma  má  resposta  ao  shear  stress  são  características  de  doentes  com  FRS  e  lesão  periférica
isquémica.
© 2016  Sociedade  Portuguesa  de  Angiologia  e  Cirurgia  Vascular.  Publicado  por  Elsevier  Espan˜a,
S.L.U. Este e´  um  artigo  Open  Access  sob  uma  licenc¸a  CC  BY-NC-ND  (http://creativecommons.
org/licenses/by-nc-nd/4.0/).
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aynaud’s  Phenomenon  (RP)  was  ﬁrst  described  by  Mau-
ice  Raynaud  in  1862  and  is  deﬁned  as  bouts  of  reversible
asospastic  ischemia  of  the  extremities.1,2 Episodic  color
hanges  of  the  ﬁngers  classically  turn  into  white  (ischemia),
hen  blue  (cyanosis)  and  red  (reperfusion).  In  a  recent  Del-
hi  exercise  round,  12  invited  experts  agreed  recently  in
hree-step  outline  for  a  newly  proposed  diagnostic  method.
onsensus  was  achieved  in  that  at  least  biphasic  color
hanges  are  required  to  make  the  diagnosis  of  RP.  They
lso  agreed  that  white/pallor  and  blue/cyanosis  were  the
wo  most  important  colors  and  that  patients  must  report
old  temperatures  as  one  of  the  triggers  for  their  RP
ttacks.3
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gPrimary  RP  (PRP),  also  known  as  Raynaud’s  disease,  is
 functional  vascular  disorder  that  occurs  isolated  as  an
xaggerated  response  to  cold  and  emotional  stress,  not  pro-
ressing  to  irreversible  tissue  injury.3,4 The  requests  for
eﬁnition  of  PRP  deﬁned  in  Delphi  exercise  round  were:
i)  normal  capillaroscopy;  (ii)  negative  physical  examination
or  ﬁndings  suggestive  of  secondary  causes  (e.g.  ulcerations,
issue  necrosis  or  gangrene,  sclerodactily,  calcinosis,  or  skin
brosis);  (iii)  no  history  of  existing  connective  tissue  disease
nd  (iv)  negative  or  low  titer  ANA.3,5
Secondary  RP  (SRP),  also  known  as  Raynaud’s  Syndrome,
ppears  in  response  to  those  triggers  too,  however,  it  occurs
n  the  setting  of  underlying  structural  vascular  disease
nd  is  often  associated  with  digital  ulceration,  scarring  or
angrene.6 Recent  advances  in  the  diagnosis  of  RP  has  have
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eVascular  biomarkers  in  Raynaud  disease  
recognized  that  abnormalities  in  nailfold  capillary  pattern
and  speciﬁc  autoantibodies  are  independent  risk  factors  for
connective  tissue  disease.4 Autoreactive  antibodies  specif-
ically  ANA,  anti-centromere  and  anti-SCL  70  antibodies  are
helpful  as  diagnostic  for  secondary  RP.
PRP  is  a  common  condition,  which  has  a  prevalence  of
3--5%  in  the  general  population.2 The  onset  age  is  below  40
years  and  there  could  be  a  history  of  PRP  in  family  but  the
entire  clinical  course  is  benign.6 By  contrast,  SRP  is  a much
rarer  condition,  but  frequent  in  the  patients  with  connec-
tive  diseases  such  as  Systemic  Sclerosis  (SSc)  (90%),  systemic
lupus  erythematous  (30%),  rheumatoid  arthritis  (20%),  Sjö-
gren’s  syndrome  and  polymiositis.
Endothelial  dysfunction  and  free-radical  damage  are  pri-
mary  events  throughout  the  course  of  the  RP  disease,  which
result  in  vascular  obliteration  and  diminished  blood  ﬂow  to
the  organs  involved7 and  are  prominent  features  of  RP  and
ischemic  peripheral  digital  ulcers.  There  are  several  serolog-
ical  biomarkers  that  reﬂect  the  vasculopathy  of  the  disease,
such  as  vasoconstrictor  ET-1,8 the  controversial  vasodilator
nitric  oxide(NO)8 and  the  inhibitor  of  endothelial  NO  syn-
thase  (eNOS)  ADMA.
Endothelial  cell  damage  results  in  ischemia-reperfusion
injury  due  to  the  ongoing  pathological  process,  which
inevitably  evolves  toward  chronic  underperfusion.  A  char-
acteristic  clinical  ﬁnding  is  capillary  dilation  and  atrophy
diagnosed  by  nailfold  capillary  microscopy.  These  ﬁndings
suggest  signiﬁcant  loss  of  the  peripheral  vascular  network
with  a  defect  in  both  the  vascular  repair  and  in  the  expected
increase  in  vessel  growth  (angiogenesis,  arteriogenesis,  vas-
culogenesis);  the  net  result  is  tissue  ischemia,  ﬁbrosis,  and
organ  failure.9
The  aim  of  the  current  study  was  to  evaluate  macrovas-
cular  disease  parameters,  endothelial  dysfunction  and
angiogenic  vascular  biomarkers  in  a  cohort  of  RP  patients,  in
an  attempt  to  deﬁne  the  boundaries  between  PRP  and  SRP
allowing  early  identiﬁcation  of  PRP  patients  who  are  at  risk
of  developing  an  underling  secondary  disease.
Materials and methods
An  observational  cohort  study  was  conducted  to  evaluate
109  RP  patients  (32  PRP  and  77  SRP)  attending  our  Mul-
tidisciplinary  Raynaud  Clinics  of  the  Clinical  Immunology
Unit  at  Centro  Hospitalar  do  Porto  in  Portugal.  We  excluded
from  our  study  all  patients  with  risk  factors  that  could
potentially  interfere  with  ﬂow-mediated  dilatation  (FMD):
smokers,  diabetics,  with  hyperlipidaemia,  and  with  past  his-
tory  of  myocardial  infarction,  as  well  as  patients  on  bosentan
treatment,  due  to  possible  interference  with  endothelin-1
levels  (ET-1).
Controls  and  PRP  patients  were  followed  for  3-years  to
ensure  no  underlying  secondary  disease.  All  77  SRP  included
patients  had  SSc  based  on  2013  classiﬁcation  criteria  for  SSc
of  American  College  of  Rheumatology.10 A  washout  of  the
vasodilator  drugs  was  done  before  inclusion  in  the  study.
Thirty-four  healthy,  sex/age  matched,  non-obese,  with-
out  self-reported  cardiovascular  risk  factors  controls  were
invited  to  participate.  No  control  subject  was  on  any  vasoac-
tive  medication.
SRP  SSc-associated  patients  were  divided  into  two
groups:  DU  group,  that  included  38  patients  having  an
a
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ctive  ischemic  ulcer  at  inclusion  (34  women;  mean  age
2.7  ±  14.8  years;  range  14--75);  and  a  39  patients  group
ith  no  history  of  DU  until  enrolment  (38  women;  mean  age
3.2  ±  10.3  years;  range  30--79).
The  institutional  ethical  review  board  of  Centro  Hospita-
ar  do  Porto  approved  this  study.  All  subjects  signed  informed
onsent  before  inclusion  in  the  study.  Data  were  collected
y  analysis  of  clinical  ﬁle  data  and  by  clinical  interview.
ethods
llen  test
llen  test  was  performed  as  follows:  (1)  instruct  patient  to
lench  his/her  ﬁst;  (2)  apply  occlusive  pressure  to  both  ulnar
nd  radial  arteries  by  ﬁnger  pressure;  (3)  conﬁrm  palm  and
nger  blanching  with  the  patient’s  hand  relaxed;  (4)  release
he  occlusive  pressure  on  ulnar  artery;  (5)  positive  test:  if
he  hand  ﬂushes  within  5--15  s,  this  indicates  that  the  ulnar
rtery  has  good  blood  ﬂow  and  palmar  arch  is  complete;
egative  test:  if  the  hand  does  not  ﬂush  within  5--15  s,  this
ndicates  that  ulnar  circulation  is  inadequate  with  an  incom-
lete  palmar  arch.
low-mediated  dilatation  (FMD)
ltrasounds  scans  were  performed  using  a  two-dimensional
ltrasonography  General  Electric  Logic  7  with  a  9  MHz  Lin-
ar  wideband  multihertz  imaging  probe.  Ultrasound  images
ere  recorded  and  analyzed  for  3  consecutive  end  diastolic
rames  (onset  of  R  wave)  at  45--60  s  after  cuff  deﬂation.  The
nter-operator  variability  was  3.6%.
Flow  mediated  dilatation  of  the  brachial  artery  in  the
ower  arm  was  evaluated  following  International  Brachial
rtery  Reactivity  Task  Force  Guidelines11 for  the  ultra-
ound  assessment  of  brachial  artery  endothelial-dependent
ow-mediated  vasodilatation.  Patients  and  controls  (healthy
ubjects)  were  on  overnight  fasting  for  12  h  before  the  ultra-
ound  study  was  performed.  The  exams  were  performed  in
he  morning,  with  patients  being  kept  in  a  quiet  temper-
ture  controlled  room  (22--24 ◦C)  for  a  preliminary  20-min
est.  Vasoactive  drugs  were  withheld  for  10  half-lives.  It  was
ssured  that  patients  did  not  exercise  or  ingest  substances
hat  could  affect  the  response  to  ischemia  like  caffeine,
itamin  C,  tobacco  or  high-fat  foods  for  24  h.
FMD  was  calculated  as  the  percentage  of  change  of
he  peak  diameter  in  response  to  reactive  hyperaemia
n  (FMD%  =  (peak  diameter  −  baseline  diameter/baseline
iameter)  ×  100).11
ascular  biomarkers
enous  blood  samples  from  fasting  individuals  were  col-
ected  into  a  serum  tube,  and  another  tube  containing
odium  heparin  (Vacuette,  Greiner-Bio-One,  Austria).  Serum
as  allowed  to  clot  at  room  temperature  and  then  sepa-
ated  from  cells  within  60  min,  and  stored  at  −70 ◦C  until
nalysis  for  asymmetric  dimethylarginine  (ADMA),  endoglin,
ndostatin,  vascular  endothelial  growth  factor  (VEGF-A).
ET-1  assessment:  Plasma  was  centrifuged  immediately  in
 refrigerated  centrifuge  and  stored  at  −70 ◦C  until  analysis
or  endothelin.  Plasma  endothelin  was  measured  using  a  RIA
ssay  (Euro-Diagnostics  AG,  Sweden).  The  resulting  values
re  reported  as  pmol/ml.
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ADMA  assessment:  Serum  was  allowed  to  clot  at  room
emperature  and  then  separated  from  cells  within  60  min
nd  stored  at  −70 ◦C  before  analysis  for  ADMA.  Serum  ADMA
as  measured  using  enzyme-linked  immunosorbent  assay
Immunodiagnostik  AG,  Germany).  The  resulting  values  are
eported  as  mol/L.
VEGF  assessment:  Serum  VEGF-A  was  measured  using
nzyme-linked  immunosorbent  assay  (IBL  International
MBH,  Germany).  The  resulting  values  were  reported  as
g/ml.
Endoglin  and  endostatin  assessment:  Serum  endoglin  and
ndostatin  were  measured  using  enzyme-linked  immunosor-
ent  assay  (Uscn,  Life  Science  Inc.,  Wuhan).  The  resulting
alues  were  reported  as  ng/ml.
tatistical  analysis
or  comparison  of  normally  distributed  scale  variables,  we
sed  unpaired  two-sided  Student’s  t-test  or  analysis  of
ariance  (Anova).  In  these  cases,  data  were  described  by
ean  ±  standard  deviation  (SD)  followed  by  the  minimal  and
he  maximal  values  (range).  Normal  distribution  was  tested
y  Q-Q  plots.  In  cases  of  non-normally  distributed  variables,
e  used  non-parametric  tests:  Mann--Whitney  and  Kruskal
allis  tests  and  data  were  described  by  median  followed  by
he  interquartile  interval  (Q1--Q3),  where  Q1 represents  the
rst  quartile  (corresponding  to  25%  of  data)  and  Q3 repre-
ents  the  third  quartile  (corresponding  to  75%  of  data).  In
nova  test,  when  the  homogeneity  of  variance  was  not  sat-
sﬁed,  we  used  the  Welch  test.  For  comparison  of  categorical
ariables,  we  used  Chi-square  or  Fisher’s  exact  probability
est.  A  receiver  operating  characteristic  (ROC)  curve  analy-
is  was  performed  to  obtain  the  predictive  accuracy  of  FMD,
ES  score,  ET-1,  ADMA,  VEGF,  endostatin  and  endoglin.  We
onsidered  p  values  <0.05  as  signiﬁcant.  Data  were  analyzed
sing  the  SPSS  software  (v.22.0,  SPSS,  Chicago,  IL).
esultshe  demographic  and  clinical  characteristics  of  the  143
ubjects  are  described  in  Tables  1  and  2.  No  major  differ-
nces  were  observed  between  SSc  patients,  PRP  patients
(
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Table  1  The  demographic  and  clinical  characteristics  of  the  143  
Variables  PRP  
Subjects,  n  32  
Age (years),  mean  ±  SD  49.9  ±  12.5  
Gender
Women,  n  (%)
25  (78.1)  
Disease  duration  (years),  median  (Q1--Q3)  15  
Mean  arterial  pressure  (mmHg),  mean  ±  SD  87.6  ±  5.6  
Total  cholesterol  (mg/dl),  mean  ±  SD  188.8  ±  8.8  
Allen  test,  positive  (%)  2  (6.3%)  
RP: Raynaud phenomenon; PRP: primary; SRP: secondary RP; SSc: syste
deviation; Q: quartile.
a Chi-square test.
b Fisher’s exact test.
c Mann--Whitney test.
* Statistical signiﬁcance for a level of 5%.I.  Silva  et  al.
nd  control  group  regarding  age,  gender,  mean  arterial
ressure  and  total  cholesterol.
Disease  duration  was  signiﬁcantly  longer  in  PRP  patients
median  value:  15  years)  compared  to  SRP  SSc  patients
median  value:  10  years)  (p  =  0.028).  All  PRP  patients  and
ontrols  had  negative  ANA  and  normal  capillaroscopy.
acrovascular  disease
acrovascular  disease  was  evaluated  by  clinical  and  hemo-
ynamic  parameters.  Only  6.3%  of  PRP  patients  had  a
ositive  Allen  test.  However  it  was  positive  in  71%  of  SRP
Sc-associated  patients  with  DU  whilst  only  18%  in  patients
ithout  DU  (p  <  0.001).
Macrovascular  ultrasound  examination  showed  no  differ-
nce  in  braquial  artery  diameter  between  groups  (p  =  0.620).
rimary  RP  (p  <  0.001), SRP  non-DU  (p  =  0.001) and  SRP  DU
p  =  0.002) had  signiﬁcantly  decreased  basal  state  PSV  com-
ared  to  control  group.  No  differences  were  found  between
RP  patients  with  and  without  DU  (p  =  0.989) (Table  3).
Flow-mediated  dilatation  at  60  s  after  deﬂation  was  sig-
iﬁcantly  lower  in  SRP  patients  (p  <  0.001).  Patients  with  DU
ad  signiﬁcantly  reduced  FMD%  (p  <  0.001)  when  compared
o  all  other  groups.  No  statistical  differences  were  found
etween  PRP  and  control  groups  (p  =  0.999)  and  between
RP  and  SRP  SSc-associated  non-DU  (p  =  0.07).  Fig.  1.  No
orrelation  was  found  between  FMD  and  disease  duration
R  =  0.41).
After  5  min  braquial  artery  occlusion,  PRP  and  SRP  had
igniﬁcant  differences  regarding  EDV  (p  <  0.001)  and  RI
p  =  0.007).  PSV  and  EDV  were  signiﬁcantly  decreased  in  SRP
roup  SSc-associated  DU  group  (p  <  0.001).  Table  3.
Vascular  disease  biomarkers  Tables  3  and  4  and  Fig.  1.
ndothelin-1
T-1  plasma  levels  were  found  to  be  signiﬁcantly  higher
p  <  0.001)  in  patients  with  both  PRP  and  SRP  SSc-associated
ompared  with  controls.  A  statistically  signiﬁcant  difference
or  ET-1  plasma  levels  was  observed  between  patients  with
RP  and  SRP  SSc-associated  patients  (p  <  0.001).
subjects.
SRP  SSc-associated  Control  p-value
DU  Non-DU
38  39  34  NA
52.7  ±  14.8  53.2  ±  10.3  47.1  ±  10.96  0.137a
34  (89.5)  38  (97.4)  29  (85.3)  0.067b
10  10  NA  0.028*,c
87.9  ±  6.04  88.3  ±  6.4  86.7  ±  6.8  0.75a
191.3  ±  9.0  187.1  ±  12.1  190.6  ±  7.6  0.242a
27  (71.1)  7  (17.9)  0  (0)  <0.001*
mic sclerosis; DU: digital ulcer; NA: non applicable; SD: standard
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Table  2  Comparison  between  SRP  SSc-DU  and  SSc  naïve  DU  groups.
Variables  SSc  DU  SSc  naïve  DU  p-value
Subjects,  n  38  39
Disease subset  0.001*,a
Limited,  n  (%)  26  (68.4)  38  (97.4)
Diffuse, n  (%)  12  (31.6)  1  (2.6)
Onset of  1st  ulcer  (years),  median  (Q1--Q2)  5  (3--13.25)  NA  NA
Telangiectasias,  positive,  n  (%)  38  (100)  27  (69.2)  <0.001*,a
Allen  test,  positive,  n  (%)  27  (71.1)  7  (17.9)  <0.001*,a
Autoantibodies
ACA,  positive,  n  (%) 22  (57.9) 27  (69.2) 0.301
Scl-70, positive,  n  (%) 12  (31.6) 6  (15.4) 0.093a
Anti-PM.  Scl,  positive,  n  (%) 2  (5.3) 5  (12.8) 0.431b
Anti-RO  52,  positive,  n  (%)  20  (52.6)  12  (30.8)  0.052a
Anti-NOR,  positive,  n  (%)  0  (0)  3  (7.7)  0.240b
Anti-ﬁbrilarin,  positive,  n  (%)  0  1  (2.6)  1.000b
Anti  U1  RNP,  positive,  n  (%)  2  (5.3)  2  (5.1)  1.000b
NVC  pattern
Early,  n  (%)  0  (0)  13  (33.3)  <0.001a
Active,  n  (%)  11  (28.9)  22  (56.4)
Late, n  (%)  27  (71.1)  4  (10.3)
SSc: systemic sclerosis; DU: digital ulcer; dcSSc: diffuse systemic sclerosis subset; lcSSc: limited systemic sclerosis subset; SRP: secondary
Raynaud phenomenon; ACA: autoantibody anti-centromere; NVC: nailfold videocapillarosocopy; MES: microangiopathy evolution score;
NA: no applicable.
a Chi-square test.
b Fisher’s exact test.
*
w
b
VStatistical signiﬁcance for a level of 5%.
Among  patients  with  SSc,  ET-1  plasma  levels  were  signiﬁ-
cantly  higher  (p  <  0.001)  in  patients  with  DU.  No  statistically
signiﬁcant  difference  for  ET-1  plasma  levels  was  observed
between  the  PRP  and  SRP  SSc  patients  without  DU.ADMA
ADMA  serum  levels  were  signiﬁcantly  higher  in  the  SRP  SSc-
associated  DU  group  (p  <  0.001). No  signiﬁcant  differences
S
a
g
f
Table  3  Comparison  of  variables  investigated  between  SRP,  PRP  
Variables  PRP  (n  =  32)  
FMD  %,  mean  ±  SD  17.96  ±  12.78  
PSV  60  s  after  cuff  deﬂation  (cm/s),
mean  ±  SD
177.69  ±  26.69  
EDV  60  s  after  cuff  deﬂation  (cm/s),
mean  ±  SD
92.95  ±  35.05  
RI,  mean  ±  SD  0.47  ±  0.23  
ET-1  pmol/ml,  median  (Q1--Q3)  7.53  (0.16--11.73)  
ADMA,  mol/L,  median  (Q1--Q3)  0.40  (0.37--0.49)  
Endoglin  ng/ml,  median  (Q1--Q3)  0.52  (0.28--0.88)  
Endostatin  ng/ml,  median  (Q1--Q3) 0.90  (0.38--1.43)  
VEGF  pg/ml,  median  (Q1--Q3) 438.50  (269.26-854.00)
SSc: systemic sclerosis; DU: digital ulcer; SRP: secondary Raynaud pheno
VEGF: vascular endothelial growth factor. FMD: ﬂow mediated dilatatio
aKruskal Wallis.
*bAnova test: Statistical signiﬁcance for a level of 5%.ere  found  between  SRP  SSc  non-DU  and  PRP  (p  =  0.757)  and
etween  PRP  and  controls  (p  =  0.204).
EGF
igniﬁcant  differences  were  found  in  VEGF  between  PRP
nd  SRP  patients  (p  <  0.001)  and  between  PRP  and  control
roup  patients  (p  <  0.001).  Lower  plasma  levels  of  VEGF  were
ound  in  patients  with  ﬁngertip  digital  ulcers  (p  <  0.001).  We
and  controls  at  baseline.
SRP-SSc  (n  =  77)  Control  (n  =  40)  p-value
10.85  ±  11.0  20.17  ±  8.86  <0.001*,b
165.35  ±  53  199.77  ±  32.93  <0.001*,b
67.28  ±  24.37  93.70  ±  20.01  <0.001*,b
0.51  ±  0.18  0.43  ±  0.08  =0.034b
11.85  (7.42--17.23)  2.48  (0.00--5.60)  <0.001*,a
0.49  (0.41--0.54)  0.38  (0.32--0.43)  <0.001*,a
2.17  (1.27--4.21)  0.28  (0.15--0.71)  <0.001*,a
0.51  (0.19--1.24)  0.565  (0.35--0.77)  0.268a
290  (166.71--361.78)  178.03  (101.27--222.10)  <0.001*,a
menon, ET-1: endothelin-1; ADMA: asymmetric dimethylarginine;
n; Q; quartile; SD: standard deviation.
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Figure  1  Graphic  representation  of  variables  investigated.  FMD  (p  <  0.001),  ET-1  (p  <  0.001),  ADMA  (p  <  0.001),  VEGF  (p  <  0.001),
Endoglin (p  <  0.001)  and  Endostatin  (p  =  0.266).  ADMA:  asymmetric  dimethylarginine;  VEGF:  vascular  endothelial  growth  factor
FMD: ﬂow  mediated  dilatation.
f
n
E
A
p
f
E
N
(
eound  no  difference  when  PRP  was  compared  to  SRP  SSc
on-DU  group  (p  =  0.099).ndoglin
ngiostatic  serum  endoglin  levels  were  increased  in  SRP
atients  with  active  DU  (p  <  0.001) and  no  signiﬁcant  dif-
erence  was  found  between  other  groups.
a
w
Pndostatin
o  signiﬁcant  differences  were  found  between  groups
p  =  0.118). Comparing  SRP  with  PRP  no  signiﬁcant  differ-
nce  was  found  (p  =  0.302).The  AU-ROC  (CI95%)  of  the  macrovascular  parameters
nd  vascular  biomarkers  investigated  associated  to  SRP
ere:  FMD  (AUC:  0.737  95%CI:  0.655--0.819);  post-occlusion
SV  (AUC:  0.681  95%CI:  0.593--0.768);  post-occlusion  EDV
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AUC:  0.766  95%CI:  0.689--0.844);  RI  (AUC:  0.634  95%CI:
.544--0.725),  ET-1  (AUC:  0.826  95%CI:  0.758--0.895);  ADMA
AUC:  0.754  95%CI:  0.675--0.832);  VEGF  (AUC:  0.508  95%CI:
.410--0.606);  endoglin  (AUC:  0.914  95%CI:  0.870--0.959)  and
ndostatin  (AUC:  0.591  95%CI:  0.463--0.720).
iscussion
e  report  here  on  the  clinical  and  laboratory  data  regarding
 large  group  of  patients  with  diagnosis  Raynaud’s  phe-
omenon.  This  is  an  observational  cohort  study  of  109  RP
atients  that  were  divided  into  two  subpopulations  PRP  and
RP,  the  latter  in  2  groups  (with  or  without  previous  ischemic
eripheral  lesions).
Clearly,  our  ﬁndings  suggest  that  endothelial  dysfunction
uggested  by  increased  serum  levels  of  ET-1  as  well  a  pro-
ngiogenic  state  due  to  increased  serum  levels  of  VEGF  are
lready  present  in  PRP  and  when  comparing  these  patients
ith  SRP  SSc-associated  without  DU  no  major  difference
ere  found  regarding  the  vascular  biomarkers  investigated.
hus,  a  new  and  useful  information  coming  out  of  this  inves-
igation  is  that  severe  obliterative  peripheral  vasculopathy
s  present  only  in  SRP  patients  with  DU  as  expressed  by  the
ncreased  peripheral  resistance,  low  FMD  response  to  shear
tress,  decreased  PSV  and  EDV  and  high  RI  mostly  consequent
f  the  EC  injury  with  endothelial  dysfunction  associated  to
n  impaired  angiogenesis.
RP  occurs  when  the  balance  of  vascular  tone  is  dis-
urbed,  favoring  vasoconstriction.  This  endothelial  activa-
ion  and/or  damage  leads  to  reduce  efﬁcacy  of  vasodilators
nd/or  overproduction  of  vasoconstrictors.4 Doubts  persist
hether  there  is  overproduction  of  endothelium  vasocon-
trictor  endothelin-1  (ET-1),  underproduction  of  vasodilators
uch  as  nitric  oxide  (NO)  and  prostacyclin,  or  whether
hey  are  impaired  in  RP.4 Further  complicating  the  role
f  NO,  patients  with  SRP  and  SSc,  have  increased  the
lasma  levels  of  an  endogenous  inhibitor  of  endothelial
OS----asymmetric  dimethyl  arginine----  (ADMA)  leading  to
educed  NO  production.12
As  a  response  to  increase  in  shear  stress,  several
asodilators  are  released  such  as  NO,  prostaglandins  and
ndothelium-derived  hyperpolarizing  factor.13 This  response
s  commonly  known  as  ﬂow-mediated  dilatation  (FMD),
nd  has  been  largely  used  for  endothelium-dependent
ysfunction  assessment.  NO  is  probably  the  major  medi-
tor  of  vasodilation  and  reduced  NO  bioavailability  has
een  broadly  accepted  as  a  marker  of  endothelium
ysfunction.14
In  our  cohort  increased  serum  levels  of  ET-1  were  present
n  PRP  and  SRP  but  only  SRP  SSc-associated  patients  with
U  had  signiﬁcantly  increased  plasma  levels  of  an  endoge-
ous  inhibitor  of  endothelial  NOS--ADMA.  This  favors  early
ndothelial  dysfunction  with  overproduction  of  vasocon-
trictors  (ET-1)  even  in  PRP  but  only  in  severe  SRP  with
eripheral  vasculopathy  is  there  an  impaired  inhibition  of
ndothelial  NOS.  Furthermore  endothelial  dependent  FMD
as  impaired  in  SRP,  whilst  PRP  and  control  groups  had  sim-lar  response  to  shear  stress.
Controversial  results  have  been  published  regarding
ndothelial  dysfunction  assessment  in  SRP  SSc  patients.
 systematic  review  and  meta-analysis15 analyzed  FMD
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ssessment  in  SSc  patients  demonstrating  that  most  of  the
tudies  (71%)  assessing  the  FMD%  found  signiﬁcantly  lower
rachial  artery  FMD%  in  SSc  patients  compared  to  controls.
he  lack  of  compensatory  increase  in  blood  ﬂow  to  the
schemic  stimulus  may  be  due  to  endothelial  dysfunction,
educed  compliance,  impaired  distensability  or  increased
rterial  stiffness.16--18
Positive  Allen  test  has  been  associated  to  RP  and  SSc.19
cclusion  of  ulnar  artery  in  SSc  patients  as  a  predictor  of  DU
as  been  reported20 probably  due  to  lack  of  compensatory
ow  of  radial/ulnar  artery  and  incomplete  palmar  arch.  In
his  study  patients  with  DU  had  more  positive  Allen  tests
ompared  to  other  groups  favoring  macrovascular  disease  in
hese  patients.
Endothelial  cell  damage  results  in  ischemia-reperfusion
njury  due  to  the  ongoing  pathological  process,  which
nevitably  evolves  toward  chronic  underperfusion.  Chronic
ypoxia  due  to  reduced  blood  ﬂow  is  not  compensated
y  efﬁcient  angiogenesis;  even  though  elevated  angiogenic
iomarkers  VEGF  in  SSc  patients  may  be  an  attempt  to
nduce  neoangiogenesis  and  capillary  neoformation.  Yet,
ncreased  serum  levels  of  angiostatic  markers,  such  as
ndoglin,  angiostatin  or  endostatin,  may  counteract  this
ctivity.12
SRP  SSc-associated  with  DU  patients  expressed  lower
EGF  and  increased  angiostatic  endoglin  serum  levels  sug-
esting  impaired  vascular  remodeling  in  response  to  the
hronic  ischemia.  No  signiﬁcant  differences  were  found
hen  PRP  and  SRP  SSc-associated  patients  with  no  periph-
ral  lesions  were  compared.
onclusion
n  conclusion  endothelial  dysfunction  and  a  pro-angiogenic
timulus  are  already  present  in  patients  with  PRP.  Macrovas-
ular  disease,  increased  peripheral  resistance  due  to
tructural  lesions  and  an  impaired  response  to  shear  stress
re  characteristic  of  SRP,  particularly  in  patients  with
eripheral  ischemic  lesions.  SRP  SSc-associated  patients
ith  DU  overproduce  endothelial  dysfunction  (ET-1  and
DMA)  and  angiostatic  (endoglin)  vascular  biomarkers.
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